Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors

Trial Profile

Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MCLA 158 (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merus
  • Most Recent Events

    • 19 Aug 2019 According to a Merus media release, the company plans to provide further guidance on the program in 2020.
    • 27 Dec 2018 According to a Merus media release, data from this study is expected at the end of 2019.
    • 24 May 2018 According to a Merus media release, the US FDA has accepted Investigational New Drug (IND) application for MCLA-158 in April 2018. The company plans to open additional sites for this trial in the United States.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top